Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY FE 1.5/30 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Acne vulgaris (off-label for females ≥15 years),Irregular menstruation (off-label)
Prevention of pregnancy
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol: primarily metabolized by CYP3A4 via hydroxylation; undergoes first-pass metabolism in the liver and gut wall. Norethindrone: primarily metabolized via reduction followed by glucuronide conjugation; some involvement of CYP3A4.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Ethinyl estradiol: ~97-98% bound to albumin; norethindrone: ~95% bound to albumin and sex hormone-binding globulin (SHBG).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Ethinyl estradiol: ~2-4 L/kg; norethindrone: ~2-4 L/kg. Reflects extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Ethinyl estradiol: 40-50% due to first-pass metabolism; norethindrone: 50-70% due to first-pass metabolism.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dosage adjustment required for renal impairment. Use with caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute hepatitis, severe cirrhosis (Child-Pugh C), or liver tumors. For mild hepatic impairment (Child-Pugh A), no adjustment; use with caution.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for premenarchal girls. For postmenarchal adolescents, same dosing as adults.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for postmenopausal women due to higher risk of thromboembolic events and lack of efficacy for contraception in this population.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially in women over 35) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Risk of thromboembolic disorders and thrombotic events (e.g., MI, stroke, DVT, PE),Increased risk of cervical cancer and breast cancer (controversial),Hepatic neoplasia (benign and malignant),Gallbladder disease,Hypertension,Impaired liver function,Carbohydrate and lipid effects,Headache/migraine,Bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Depression,Contact lens intolerance,Fluid retention
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Current or history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer or personal history of breast cancer,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior OCP use,Hepatic adenomas or carcinomas,Known or suspected pregnancy,Hypersensitivity to any component,Major surgery with prolonged immobilization,Smoking in women over 35 years old,Current or history of migraine with focal aura if >35 years old,Current or history of hypertension with vascular disease
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels but effect is not clinically significant; no restriction. Iron absorption may be enhanced by vitamin C (e.g., citrus); avoid taking with dairy or antacids that reduce iron absorption, separate by at least 2 hours if needed.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Category X: Contraindicated in pregnancy. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimesters: Associated with fetal adrenal suppression, hepatic dysfunction, and masculinization of female fetuses. Discontinue immediately if pregnancy occurs.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in breast milk in low amounts (estrogen M/P ratio ~0.2; progestin M/P ~0.3). Theoretical risk of reduced milk production and infant jaundice. Use only if benefits outweigh risks; consider alternative contraception.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy. No indication for use; pharmacokinetic changes (increased clearance, protein binding changes) are irrelevant as use is prohibited.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
HAILEY FE 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 µg and norethindrone 1.5 mg, with iron supplementation (ferrous fumarate 75 mg). The iron component is not part of the contraceptive effect but helps maintain iron stores during menstruation. It is typically taken for 21 active pills followed by 7 placebo pills (containing iron). Administer consistently at the same time daily to maintain hormone levels and minimize breakthrough bleeding. Monitor for elevated blood pressure, thromboembolic events, and hepatic adenoma. Smoking increases cardiovascular risk; avoid in women over 35 who smoke. Efficacy may be reduced with hepatic enzyme-inducing drugs (e.g., rifampin, certain anticonvulsants).
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time each day, even if you do not have sex.,The first 21 pills are active hormones; the last 7 pills (green) contain iron and are placebos.,If you miss a pill, follow the package instructions: take the missed pill as soon as remembered, and use backup contraception if you miss more than one.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Smoking while on this pill increases risk of serious cardiovascular events; do not smoke.,Contact your healthcare provider if you experience leg pain, chest pain, sudden severe headache, or visual changes.,HAILEY FE does not protect against HIV or other sexually transmitted infections; use condoms for protection.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you have severe vomiting or diarrhea, use additional contraception.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HAILEY FE 1.5/30 vs ALYACEN 1/35, answered by our medical review team.
HAILEY FE 1.5/30 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HAILEY FE 1.5/30 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HAILEY FE 1.5/30 is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HAILEY FE 1.5/30 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HAILEY FE 1.5/30 is classified as Category C. Category X: Contraindicated in pregnancy. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimesters: Ass. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.